Literature DB >> 3968643

Reactivity and possible significance of hydroxylamine and nitroso metabolites of procainamide.

J P Uetrecht.   

Abstract

We have demonstrated previously that procainamide is metabolized to a hydroxylamine. The reactivities of this hydroxylamine and of the closely related nitroso derivative toward biological molecules were investigated with the objective of exploring possible mechanisms of procainamide-induced lupus. The hydroxylamine of procainamide was found to bind covalently to microsomal protein to a much greater degree than did procainamide and, in contrast to procainamide, it did not require metabolic activation. However, the hydroxylamine is readily converted nonenzymatically to the nitroso derivative, and reducing agents such as ascorbate and NADPH, which reduce the nitroso derivative to the hydroxylamine, blocked covalent binding. This suggests that the nitroso derivative is the reactive species for covalent binding. Furthermore, glutathione had been shown previously to block covalent binding of procainamide metabolites, and the nitroso derivative, but not the hydroxylamine, reacted rapidly with glutathione forming a sulfinamide derivative. The covalent binding of the nitroso derivative to microsomal protein appears to involve sulfydryl groups, because it, like the glutathione adduct, was readily cleaved by mild acid. In contrast, the nature of the covalent binding to albumin and histone protein appears different from that to microsomal protein in that most of the binding was stable to mild acid. The reactivity toward DNA was much less than that to protein. The observation that both the reactivity of nitrosoprocainamide and the specificity of antinuclear antibodies in procainamide-induced lupus are to histone protein rather than the DNA supports the hypothesis that this reactive metabolite plays a role in the etiology of procainamide-induced lupus.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3968643

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  19 in total

1.  Acrylamine-induced autoimmune phenomena.

Authors:  Bruce Rothschild
Journal:  Clin Rheumatol       Date:  2010-06-11       Impact factor: 2.980

Review 2.  Idiosyncratic drug reactions: possible role of reactive metabolites generated by leukocytes.

Authors:  J P Uetrecht
Journal:  Pharm Res       Date:  1989-04       Impact factor: 4.200

Review 3.  Drug-related lupus. Incidence, mechanisms and clinical implications.

Authors:  L E Adams; E V Hess
Journal:  Drug Saf       Date:  1991 Nov-Dec       Impact factor: 5.606

Review 4.  Immunotoxic side-effects of drug therapy.

Authors:  J A Mitchell; E M Gillam; L A Stanley; E Sim
Journal:  Drug Saf       Date:  1990 May-Jun       Impact factor: 5.606

5.  Metabolomics reveals the metabolic map of procainamide in humans and mice.

Authors:  Fei Li; Andrew D Patterson; Kristopher W Krausz; Bernhard Dick; Felix J Frey; Frank J Gonzalez; Jeffrey R Idle
Journal:  Biochem Pharmacol       Date:  2012-02-24       Impact factor: 5.858

6.  Autoimmunity caused by disruption of central T cell tolerance. A murine model of drug-induced lupus.

Authors:  A Kretz-Rommel; S R Duncan; R L Rubin
Journal:  J Clin Invest       Date:  1997-04-15       Impact factor: 14.808

7.  Direct and metabolism-dependent toxicity of sulphasalazine and its principal metabolites towards human erythrocytes and leucocytes.

Authors:  M Pirmohamed; M D Coleman; F Hussain; A M Breckenridge; B K Park
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

Review 8.  Mechanisms of unpredictable adverse drug reactions.

Authors:  M J Rieder
Journal:  Drug Saf       Date:  1994-09       Impact factor: 5.606

Review 9.  Role of reactive metabolites in the circulation in extrahepatic toxicity.

Authors:  Roy M Irving; Adnan A Elfarra
Journal:  Expert Opin Drug Metab Toxicol       Date:  2012-06-11       Impact factor: 4.481

Review 10.  Acecainide (N-acetylprocainamide). A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiac arrhythmias.

Authors:  D W Harron; R N Brogden
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.